A BLA has been filed for bentracimab and, if approved, has the potential to be the first therapy to reverse the effects of Brilinta for patients who have bleeding events or who need urgent surgery.

Background: Dual antiplatelet therapy is the standard of care for acute coronary syndrome, but uncertainty exists regarding ...

In patients with acute coronary syndrome (ACS), coronary artery bypass graft (CABG) surgery performed 2-3 days after ticagrelor cessation was noninferior in bleeding risk and reduced hospital stay ...

An investigational monoclonal antibody called bentracimab can safely and effectively reverse potentially catastrophic ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

The OMOP CDM harmonises data across research networks using a uniform structure and analysis software among diverse entities.12 13 This study was approved by the Institutional Review Board of Kangdong ...

The skin is the largest organ in the human body, serving as a complex and versatile protective barrier between the internal organs and the external environment. Its intricate structure plays a pivotal ...

The Company History page lists out the major events in chronological order for AstraZeneca Pharma India Ltd. Company History - AstraZeneca Pharma India Ltd.